DAPAGLIFLOZINA 5 MG COM REV CT BL AL/AL X 30
Apresentação · Câmara de Regulação do Mercado de Medicamentos (CMED), Secretaria Executiva exercida pela Agência Nacional de Vigilância Sanitária (ANVISA) · Brasil
-
Número de registro
1053502580034 -
GGREM
517626090035607 -
Código de barras
7899620918313
O que a fonte publica
- Detentor do registro
- LABORATORIO GLOBO SA
- Princípios ativos
- DAPAGLIFLOZINA
- Embalagem
- 5 MG COM REV CT BL AL/AL X 30
- Regime de dispensação
- Tarja Vermelha
- Tipo de produto
- Genérico
- Classe terapêutica
- A10P1 - ANTIDIABÉTICOS INIBIDORES DE SGLT2, PUROS
- Prescrição
- Sob prescrição ou restrito
Nomes pelos quais este registro é encontrado
Dados completos da fonte
{
"name": "DAPAGLIFLOZINA 5 MG COM REV CT BL AL/AL X 30",
"holder": "LABORATORIO GLOBO SA",
"stripe": "Tarja Vermelha",
"barcodes": [
"7899620918313"
],
"confaz87": false,
"currency": "BRL",
"marketed": null,
"ggremCode": "517626090035607",
"useDomain": "unknown",
"capApplies": null,
"icmsExempt": false,
"holderTaxId": "17.115.437/0001-73",
"priceRegime": "Regulado",
"productName": "DAPAGLIFLOZINA",
"productType": "Genérico",
"hospitalOnly": false,
"presentation": "5 MG COM REV CT BL AL/AL X 30",
"sourceStatus": null,
"supplyRegime": "Tarja Vermelha",
"factoryPrices": {
"icms-0": "46.75",
"icms-12": "53.13",
"icms-17": "56.33",
"icms-18": "57.01",
"icms-19": "57.72",
"icms-20": "58.44",
"icms-21": "59.18",
"icms-22": "59.94",
"icms-23": "60.71",
"icms-17.5": "56.67",
"icms-19.5": "58.07",
"icms-20.5": "58.81",
"icms-22.5": "60.32",
"icms-12-alc": "52.49",
"icms-17-alc": "55.65",
"icms-18-alc": "56.33",
"icms-19-alc": "57.02",
"icms-20-alc": "57.74",
"icms-21-alc": "58.47",
"icms-22-alc": "59.22",
"icms-23-alc": "59.99",
"withoutTaxes": "46.19",
"icms-17.5-alc": "55.99",
"icms-19.5-alc": "57.38",
"icms-20.5-alc": "58.10",
"icms-22.5-alc": "59.60"
},
"pisCofinsList": "Positiva",
"substanceText": "DAPAGLIFLOZINA",
"targetSpecies": [],
"consumerPrices": {
"icms-0": "64.44",
"icms-12": "73.23",
"icms-17": "77.65",
"icms-18": "78.58",
"icms-19": "79.56",
"icms-20": "80.55",
"icms-21": "81.57",
"icms-22": "82.62",
"icms-23": "83.68",
"icms-17.5": "78.11",
"icms-19.5": "80.04",
"icms-20.5": "81.06",
"icms-22.5": "83.14",
"icms-12-alc": "72.56",
"icms-17-alc": "76.93",
"icms-18-alc": "77.87",
"icms-19-alc": "78.83",
"icms-20-alc": "79.82",
"icms-21-alc": "80.83",
"icms-22-alc": "81.87",
"icms-23-alc": "82.93",
"withoutTaxes": "63.85",
"icms-17.5-alc": "77.40",
"icms-19.5-alc": "79.32",
"icms-20.5-alc": "80.32",
"icms-22.5-alc": "82.39"
},
"invalidBarcodes": [],
"activeSubstances": [
"DAPAGLIFLOZINA"
],
"therapeuticClass": "A10P1 - ANTIDIABÉTICOS INIBIDORES DE SGLT2, PUROS",
"commercialisation": {
"year": 2025,
"marketed": false
},
"priceAnalysisNote": null,
"useDomainEvidence": {
"basis": "unreviewed",
"field": null,
"value": null,
"version": 1,
"sourceId": "br.anvisa.cmed-prices"
},
"patientEligibility": "not-assessed",
"registrationNumber": "1053502580034",
"targetSpeciesStatus": "not-reported",
"administrativeStatus": "unknown",
"prescriptionCategory": "prescription-or-restricted",
"prescriptionRequired": true,
"therapeuticClassCode": "A10P1",
"commercialDestination": null,
"registrationNumberFlag": null
}
Leia este registro a partir do seu próprio software
O mesmo registro, com todos os campos e sua procedência, está a uma requisição de distância. A chave de API é gratuita e funciona imediatamente.
curl -G "https://api.medifontis.com/v1/drugs/record" \
-H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
--data-urlencode "country=br" \
--data-urlencode "sourceId=br.anvisa.cmed-prices" \
--data-urlencode "id=br:cmed:presentations:517626090035607"